<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><atom:link href="https://www.pccarx.ca/DesktopModules/LiveBlog/API/Syndication/GetRssFeeds?Tag=usp-800-revisions&amp;mid=8604&amp;PortalId=0&amp;tid=999&amp;ItemCount=20" rel="self" type="application/rss+xml" /><title>THE PCCA BLOG</title><description>Stay current on PCCA news and events, market trends, and all things compounding!</description><link>https://www.pccarx.ca/Blog</link><item><title>USP 797: Revisions &amp; Impacts, Part 2</title><link>https://www.pccarx.ca/Blog/usp-797-revisions-impacts-part-2?PostId=297</link><category>Pharmacy Legislation/Regulation</category><pubDate>Wed, 08 Mar 2023 12:00:00 GMT</pubDate><description>&lt;div class="PCCABlogPost"&gt;
&lt;p&gt;&lt;em&gt;by Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;If you missed Part 1 of &lt;strong&gt;USP 797: Revisions &amp; Impacts&lt;/strong&gt;, it can be found &lt;a href="https://www.pccarx.com/Blog/usp-797-revisions-impacts-part-1" target="_blank"&gt;&lt;strong&gt;here&lt;/strong&gt;.&lt;/a&gt;&lt;/em&gt;&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt;ENVIRONMENTAL MONITORING&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;Personnel compounding Category 3 sterile preparations are required to perform media fills with glove fingertip sampling and surface sampling of the direct compounding area at least every three months, compared to at least every six months for those compounding Category 1 or 2 sterile preparations.&lt;/p&gt;

&lt;p&gt;Pharmacies compounding Category 3 sterile preparations also require more frequent monitoring. Thirty days prior to starting to compound any Category 3 batches, viable air sampling must be conducted. Viable air sampling using an impaction device must be completed for each classified area monthly for facilities preparing Category 3 sterile preparations, compared to every six months for facilities preparing Category 1 or 2 preparations.&lt;/p&gt;

&lt;p&gt;Surface sampling is required weekly for Category 3 sterile preparations and must be performed in the ISO 5 with each batch of a Category 3 CSP unless using a self-enclosed robotic device. By contrast, for Category 1 or Category 2 preparations, surface sampling is required monthly. Surface sampling must be done in all classified areas and pass-throughs. The sampling must include:&lt;/p&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;
	&lt;p&gt;Each classified area, including each room&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;The interior of each ISO Class 5 primary engineering control (PEC)&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Pass-through chambers connecting to classified areas&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Equipment contained within the PEC&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Staging or work area(s) near the PEC&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Frequently touched surfaces&lt;/p&gt;
	&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Pharmacies must also conduct viable air sampling and surface sampling:&lt;/p&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;
	&lt;p&gt;When new facilities and equipment are certified&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;After servicing any facility or equipment (see Section 4, &lt;em&gt;Facilities and Engineering Controls&lt;/em&gt;)&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;After identifying any problem (e.g., microbial growth in preparation sterility tests)&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;After identifying any problematic trends (e.g., failed fingertip/thumb sampling results, failed media-fill testing, or repeated air or surface contamination)&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Any changes are made to the facility or processes that could impact the compounding environment (e.g., change in cleaning agents)&lt;/p&gt;
	&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Pharmacies must also conduct total airborne particle-count testing in all classified areas during dynamic operating conditions at least every six months for all categories of sterile preparations.&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt;CLEANING AND SANITIZING&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;Cleaning and sanitizing procedures also changed in Chapter 797 revisions. Pharmacies must clean surfaces prior to disinfecting them unless they use EPA-registered (or equivalent outside the U.S.) one-step disinfectant cleaners that simultaneously clean and disinfect with an appropriate contact time specified by the product.&lt;/p&gt;

&lt;p&gt;In a PEC, after cleaning and disinfecting, pharmacies must apply sterile 70% isopropyl alcohol (IPA) to remove any residues of the product(s). Sterile 70% IPA must also be applied immediately before initiating compounding.&lt;/p&gt;

&lt;p&gt;Another significant difference exists in the frequency of sporicidal application between Categories 1 and 2 and Category 3 preparations. When pharmacies create Category 3 preparations, they must apply a sporicidal agent to the PEC, including the removable work tray (if applicable), the equipment and work surfaces outside the PEC (pass-throughs and floors) at least weekly. Compounding Categories 1 and 2 preparations require monthly application of a sporicidal agent to all areas.&lt;/p&gt;

&lt;p&gt;Along with these changes, the process for cleaning and disinfecting the PEC received more detailed directions. Compounders must:&lt;/p&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;
	&lt;p&gt;If necessary, remove visible particles, debris or residue with an appropriate solution (e.g., Sterile Water for Injection or Sterile Water for Irrigation) using sterile, low-lint wipers.&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Use a sterile low-lint wiper, apply a sterile cleaning agent followed by a sterile EPA-registered disinfectant, or apply a sterile EPA-registered (or equivalent for entities outside the U.S.) one-step disinfectant cleaner to equipment and all PEC interior surfaces.&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Ensure the contact time specified by the manufacturer is achieved.&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Use a sterile low-lint wiper, apply sterile 70% IPA to equipment and all PEC interior surfaces.&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Allow the surface to dry completely before beginning compounding.&lt;/p&gt;
	&lt;/li&gt;
&lt;/ul&gt;

&lt;h2&gt;&lt;strong&gt;WHAT COMES NEXT&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;USP 795 and 797 are official and possibly enforceable in your state on November 1, 2023. Revisions to USP 795 and 797 also make USP Chapter 800, &lt;em&gt;Hazardous Drugs — Handling in Healthcare Settings, &lt;/em&gt;“compendially applicable” (USP term) and possibly enforceable in many states on November 1, 2023. For more information on Chapter 800, visit pccarx/&lt;u&gt;&lt;a href="https://www.pccarx.com/usp800" target="_blank"&gt;USP Update/800&lt;/a&gt;&lt;/u&gt;.&lt;/p&gt;

&lt;p&gt;PCCA offers resources to help pharmacies navigate the changing compounding standards and regulatory environment, including our blog on &lt;u&gt;&lt;a href="https://www.pccarx.com/Blog/2-fda-resources-that-can-help-protect-patients-minimize-risk-in-your-pharmacy" target="_blank"&gt;FDA Insanitary Conditions&lt;/a&gt;&lt;/u&gt;&lt;u&gt; &lt;/u&gt;and limited USP training courses at &lt;u&gt;&lt;a href="https://www.pccarx.com/PCCANews/PCCAopensregistrationtoallcompoundersforpharmacycompoundingtrainingcoursesonqualitycomplianceandregulatoryrequirements" target="_blank"&gt;eLearning Compounding Training&lt;/a&gt;&lt;/u&gt;.&lt;em&gt; &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;PCCA offers additional resources to our &lt;u&gt;&lt;a href="https://www.pccarx.com/Membership" target="_blank"&gt;members&lt;/a&gt;&lt;/u&gt;, including all courses offered in our &lt;u&gt;&lt;a href="https://pccarx.com/PCCAEducation/eLearning" target="_blank"&gt;eLearning Compounding Training&lt;/a&gt;&lt;/u&gt;, multiple &lt;u&gt;&lt;a href="https://pccarx.com/PCCAEducation/Pharmacy" target="_blank"&gt;online webinars and training sessions&lt;/a&gt;&lt;/u&gt; and, for members with Clinical Services, &lt;u&gt;&lt;a href="https://pccarx.com/PCCAEducation/SpeakersBureau" target="_blank"&gt;Speakers Bureau&lt;/a&gt;&lt;/u&gt; to guide, assist and educate compounding pharmacy staff. Members with Clinical Services may also contact our Clinical Services team for help with formulas and other compounding concerns.&lt;/p&gt;

&lt;p&gt;&lt;br /&gt;
&lt;em&gt;The complete version of this article originally appeared in PCCA’s members-only magazine, the Apothagram.&lt;/em&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div id="addName" style="display: none;"&gt;membership&lt;/div&gt;</description><guid isPermaLink="false">297</guid></item><item><title>USP 797: Revisions &amp; Impacts, Part 1</title><link>https://www.pccarx.ca/Blog/usp-797-revisions-impacts-part-1?PostId=294</link><category>Pharmacy Legislation/Regulation</category><pubDate>Wed, 01 Mar 2023 12:00:00 GMT</pubDate><description>&lt;div class="PCCABlogPost"&gt;
&lt;p&gt;&lt;em&gt;by Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services&lt;/em&gt;&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt;USP 797 Revisions&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;USP offers a number of tools for USP 797 revisions, including:&lt;/p&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;u&gt;&lt;a href="https://go.usp.org/USP_GC_797_FAQs" target="_blank"&gt;USP 797 FAQs&lt;/a&gt;&lt;/u&gt;&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;u&gt;&lt;a href="https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/usp-nf-commentary/797-commentary-20221101.pdf?_ga=2.268852657.1596023849.1670518118-1266414170.1655818579" target="_blank"&gt;USP 797 Commentary&lt;/a&gt;&lt;/u&gt;&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;u&gt;&lt;a href="https://uspevents.webex.com/recordingservice/sites/uspevents/recording/0b59cac041c3103ba7ff1ebdf322dde7/playback" target="_blank"&gt;USP 797 Open Forum Presentation&lt;/a&gt;&lt;/u&gt; presented and recorded on November 8, 2022&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;u&gt;&lt;a href="https://www.usp.org/sites/default/files/usp/document/events-and-training/2022-11-08-gc-797-open-forum-website-posting.pdf" target="_blank"&gt;USP 797 Open Forum Slides&lt;/a&gt;&lt;/u&gt; presented on November 8, 2022&lt;/p&gt;
	&lt;/li&gt;
&lt;/ul&gt;

&lt;h2&gt;&lt;strong&gt;CSP Categories &lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;Category 1 CSPs are compounded under the least controlled environmental conditions and assigned a BUD of 12 hours or less at controlled room temperature or 24 hours or less when refrigerated (see USP 797 revisions for additional requirements). Category 2 CSPs require more environmental controls and testing and may be assigned a BUD of greater than 12 hours at controlled room temperature or more than 24 hours if refrigerated. Category 2 CSP formulations may not exceed BUD limits established in Table 13 of 797 revisions.&lt;/p&gt;

&lt;p&gt;Revisions to USP 797 contain Category 3 CSPs, which offer longer possible BUDs compared to Category 1 and Category 2 CSPs. Category 3 BUDs are found in Table 14 of the revised Chapter 797 (see below).&lt;/p&gt;

&lt;center&gt;
&lt;table cellpadding="0" cellspacing="0" width="610"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td colspan="4" width="610"&gt;
			&lt;p&gt;&lt;strong&gt;TABLE 14. BUD LIMITS FOR CATEGORY 3 CSPs&lt;/strong&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td width="279"&gt;
			&lt;p&gt;&lt;strong&gt;Compounding Method&lt;/strong&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td width="127"&gt;
			&lt;p&gt;&lt;strong&gt;Controlled Room Temp. (20 – 25&lt;/strong&gt;&lt;strong&gt;&lt;sup&gt;o &lt;/sup&gt;&lt;/strong&gt;&lt;strong&gt;C)&lt;/strong&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td width="103"&gt;
			&lt;p&gt;&lt;strong&gt;Refrigerated (2 – 8&lt;/strong&gt;&lt;strong&gt;&lt;sup&gt;o &lt;/sup&gt;&lt;/strong&gt;&lt;strong&gt;C)&lt;/strong&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td width="101"&gt;
			&lt;p&gt;&lt;strong&gt;Freezer(-25 – -10&lt;/strong&gt;&lt;strong&gt;&lt;sup&gt;o &lt;/sup&gt;&lt;/strong&gt;&lt;strong&gt;C)&lt;/strong&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td width="279"&gt;
			&lt;p&gt;Aseptically processed, sterility tested and passing all applicable tests for Category 3 CSPs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td width="127"&gt;
			&lt;p&gt;60 days&lt;/p&gt;
			&lt;/td&gt;
			&lt;td width="103"&gt;
			&lt;p&gt;90 days&lt;/p&gt;
			&lt;/td&gt;
			&lt;td width="101"&gt;
			&lt;p&gt;120 days&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td width="279"&gt;
			&lt;p&gt;Terminally sterilized, sterility tested and passing all applicable tests for Category 3 CSPS&lt;/p&gt;
			&lt;/td&gt;
			&lt;td width="127"&gt;
			&lt;p&gt;90 days&lt;/p&gt;
			&lt;/td&gt;
			&lt;td width="103"&gt;
			&lt;p&gt;120 days&lt;/p&gt;
			&lt;/td&gt;
			&lt;td width="101"&gt;
			&lt;p&gt;180 days&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;
&lt;/center&gt;

&lt;p&gt;&lt;br /&gt;
Category 3 CSPs have a number of additional requirements. For example, Category 3 CSPs must be supported by a stability-indicating assay validated using USP 1225, &lt;em&gt;Validation of Compendial Procedures&lt;/em&gt;. The sterile preparation must follow the same ingredients and procedures as the stability assay, as well as packaged using the exact container-closure system and made of the same materials used in the study.&lt;/p&gt;

&lt;p&gt;Category 3 CSPs, such as injectables or ophthalmic solutions, must pass the appropriate particulate matter test once for each formulation. Injections must pass particulate testing according to USP 788, &lt;em&gt;Particulate Matter in Injections&lt;/em&gt;, while ophthalmic solutions must pass particulate testing according to USP 789, &lt;em&gt;Particulate Matter in Ophthalmic Solutions&lt;/em&gt;. Additionally, the container-closure systems used for injections and ophthalmic solutions must pass testing according to USP 1207, &lt;em&gt;Package Integrity Evaluation — Sterile Products&lt;/em&gt;, for each formulation. Both Category 2 and Category 3 multidose CSPs must pass antimicrobial effectiveness testing in accordance with USP 51.&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt;ENDOTOXIN TESTING&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;Category 1 sterile preparations do not require endotoxin testing. Category 2 sterile injectable preparations compounded from one or more nonsterile components and assigned a BUD that requires sterility testing must be tested for endotoxin content in accordance with USP 85, &lt;em&gt;Bacterial Endotoxins&lt;/em&gt;. If a Category 2 sterile preparation is compounded from one or more nonsterile components but is assigned a BUD that does not require sterility testing, endotoxin testing is not required; however, endotoxin testing is suggested. Category 3 sterile injectable preparations compounded from one or more nonsterile component(s) must be tested for endotoxin content.&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt;GARBING PRACTICES&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;Beyond the data and test(s) supporting the formulation, additional requirements exist in the revisions to 797 for everyone entering a buffer room where Category 3 CSPs are prepared. Anyone entering a buffer room where Category 3 CSPs are prepared must follow stricter garbing practices:&lt;/p&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;
	&lt;p&gt;Compounders are not allowed any exposed skin in the buffer room (e.g., face and neck must be covered).&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;All low-lint outer garb must be sterile, including the use of sterile sleeves over gauntlet sleeves when restricted access barrier system (RABS is used.&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Once a compounder leaves a classified area, disposable garbing items must be discarded and laundered garb must not be reused without being laundered and re-sterilized with a validated cycle.&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;The facility’s SOPs must describe disinfection procedures for reusing goggles, respirators and other reusable equipment.&lt;/p&gt;
	&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;PCCA offers resources to help pharmacies navigate the changing compounding standards and regulatory environment, including our blog on &lt;u&gt;&lt;a href="https://www.pccarx.com/Blog/2-fda-resources-that-can-help-protect-patients-minimize-risk-in-your-pharmacy" target="_blank"&gt;FDA Insanitary Conditions&lt;/a&gt;&lt;/u&gt;and limited USP training courses at &lt;u&gt;&lt;a href="https://www.pccarx.com/PCCANews/PCCAopensregistrationtoallcompoundersforpharmacycompoundingtrainingcoursesonqualitycomplianceandregulatoryrequirements" target="_blank"&gt;eLearning Compounding Training&lt;/a&gt;&lt;/u&gt;.&lt;/p&gt;

&lt;p&gt;PCCA offers additional resources to our &lt;u&gt;&lt;a href="https://www.pccarx.com/Membership" target="_blank"&gt;members&lt;/a&gt;&lt;/u&gt;, including all courses offered in our &lt;u&gt;&lt;a href="https://pccarx.com/PCCAEducation/eLearning" target="_blank"&gt;eLearning Compounding Training&lt;/a&gt;&lt;/u&gt;, multiple &lt;u&gt;&lt;a href="https://pccarx.com/PCCAEducation/Pharmacy" target="_blank"&gt;online webinars and training sessions&lt;/a&gt;&lt;/u&gt; and, for members with Clinical Services, &lt;u&gt;&lt;a href="https://pccarx.com/PCCAEducation/SpeakersBureau" target="_blank"&gt;Speakers Bureau&lt;/a&gt;&lt;/u&gt; to guide, assist and educate compounding pharmacy staff. Members with Clinical Services may also contact our Clinical Services team for help with formulas and other compounding concerns.&lt;/p&gt;

&lt;p&gt;&lt;em&gt;P&lt;/em&gt;&lt;em&gt;&lt;em&gt;ar&lt;/em&gt;t 2 of &lt;strong&gt;USP 797: Revisions &amp; Impacts, &lt;/strong&gt;can be found &lt;a href="https://www.pccarx.com/Blog/usp-797-revisions-impacts-part-2" target="_blank"&gt;&lt;strong&gt;here&lt;/strong&gt;.&lt;/a&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;The complete version of this article originally appeared in PCCA’s members-only magazine, the Apothagram.&lt;/em&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div id="addName" style="display: none;"&gt;membership&lt;/div&gt;
</description><guid isPermaLink="false">294</guid></item><item><title>USP 795: Revisions &amp; Impacts, Part 2</title><link>https://www.pccarx.ca/Blog/usp-795-revisions-impacts-part-2?PostId=286</link><category>Pharmacy Legislation/Regulation</category><pubDate>Wed, 15 Feb 2023 13:30:23 GMT</pubDate><description>&lt;div class="PCCABlogPost"&gt;
&lt;p&gt;&lt;em&gt;by Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;If you missed Part 1 of our &lt;strong&gt;USP 795: Revisions &amp; Impacts, &lt;/strong&gt;it&lt;strong&gt; &lt;/strong&gt;can be found &lt;a href="https://www.pccarx.com/Blog/usp-795-revisions-impacts-part-1" target="_blank"&gt;&lt;strong&gt;here&lt;/strong&gt;.&lt;/a&gt;&lt;/em&gt;&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt; Beyond Use Dates&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;&lt;strong&gt;&lt;/strong&gt;The concept of water activity receives significant discussion in the revisions to 795. Water activity is a measure of the water that is unbound and freely available to participate in chemical, biochemical or physicochemical reactions, or provides an environment that supports microbial growth. Compounded preparations with a water activity less than 0.6 are considered anhydrous with extended BUDs because they are less likely to allow degradation of API or microbial growth. Discussions on water activity were expanded in 795 revisions and examples of the water activity of various dosage forms were added to the chapter (USP 1112 also discusses water activity).&lt;/p&gt;

&lt;p&gt;The maximum potential BUDs that can be assigned to compounded nonsterile preparations without additional stability testing has changed. Nonaqueous topicals, suppositories and troches are now preparations that allow up to 180-day expanded BUDs. Nonaqueous oral preparations can be assigned up to a 90-day BUD. Aqueous dosage forms are separated based on whether or not they have a preservative: non-preserved aqueous dosage forms may be given up to a 14-day BUD when stored at refrigerated temperature; preserved aqueous dosage forms may be given up to a 35-day BUD at room temperature or under refrigeration.&lt;/p&gt;

&lt;p&gt;BUDs may extend up to 180 days with a stability study (published or unpublished) using a stability-indicating assay for the API(s), CNSP and type(s) of container closure used. If the BUD of an aqueous preparation is extended, the formulation must also be tested for the performance of the preservative, known as antimicrobial effectiveness testing, according to USP Chapter 51. Revisions to Chapter 795 also permit use of bracketing for stability studies and antimicrobial effectiveness testing. Bracketing is performing tests on a low concentration and a high concentration of API(s). If the formulation passes the tests at both concentrations, the data can be applied to all strengths that fall between the two that were tested.&lt;/p&gt;

&lt;p&gt;PCCA has developed over &lt;a href="http://www.pccarx.com/science" target="_blank"&gt;200 FormulaPlus&lt;sup&gt;™&lt;/sup&gt; formulas&lt;/a&gt; tested with stability-indicating assays and USP 51 antimicrobial effectiveness (when applicable) for extended BUDs. Some of these are bracketed formulations to help PCCA members address the variety of strengths prescribed by practitioners. FormulaPlus&lt;sup&gt;™&lt;/sup&gt; formulas meet all requirements in USP 795 revisions.&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt;THE DESIGNATED PERSON(S)&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;Responsibility for the performance of the compounding operation created a new role, called the “designated person(s) (DP),” which holds one or more people responsible and accountable for the performance and operation of the facility and personnel preparing CNSPs. The DP(s) is tasked with over 20 areas of responsibility. Note a pharmacy can have one or several persons as the designated person(s), hence the “(s).” These responsibilities can therefore be divided among team members who are appropriate for each responsibility. A few DP(s) key responsibilities are training, documentation and quality control/assurance. While training was discussed above, it is imperative to highlight documentation, including:&lt;/p&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;
	&lt;p&gt;Personnel training, competency assessments and qualification records, with corrective actions for any failures&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Equipment records (e.g., calibration, verification and maintenance reports)&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Certificates of analysis and all documentation required for components not conventionally manufactured&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Receipt of components&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Standard operating procedures, master formulation records and compounding records&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Release-inspection and testing records&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Information related to complaints and adverse events, including corrective actions taken&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Results of investigations and corrective actions&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Records of cleaning and sanitizing the designated compounding area&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Temperature logs&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Accommodations to personnel compounding CNSPs&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Any required routine review (e.g., yearly review of quality assurance and quality control programs, yearly review of chemical hazard and disposal information)&lt;/p&gt;
	&lt;/li&gt;
&lt;/ul&gt;

&lt;div&gt;USP 795 references USP 1163 on quality assurance, which can be a helpful resource in developing the required formal written quality assurance and quality control program. This program should establish a system of:&lt;/div&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;
	&lt;p&gt;Adherence to procedures&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Prevention and detection of errors and other quality problems&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Evaluation of complaints and adverse events&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;Appropriate investigations and corrective actions, such as:&lt;/p&gt;
	&lt;/li&gt;
&lt;/ul&gt;

&lt;ol style="margin-left: 40px;"&gt;
	&lt;li&gt;
	&lt;p&gt;Determining when recalls must be initiated, including procedures to immediately notify the prescriber of a failure of specifications with the potential to cause patient harm (e.g., strength, purity or other quality attributes)&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;Determining the distribution of any affected CNSP, including other affected lots, and the date and quantity of distribution&lt;/li&gt;
	&lt;li&gt;Identifying patients who received the CNSP&lt;/li&gt;
	&lt;li&gt;Recalling any unused dispensed stock and quarantining any remaining stock&lt;/li&gt;
	&lt;li&gt;Disposing of the recalled CNSP and documentation&lt;/li&gt;
&lt;/ol&gt;

&lt;div&gt; &lt;/div&gt;

&lt;p&gt;PCCA offers resources to help pharmacies navigate the changing compounding standards and regulatory environment, including our blog on &lt;u&gt; &lt;a href="https://www.pccarx.com/Blog/2-fda-resources-that-can-help-protect-patients-minimize-risk-in-your-pharmacy" target="_blank"&gt; FDA Insanitary Conditions &lt;/a&gt; &lt;/u&gt; &lt;u&gt; &lt;/u&gt; and limited USP training courses at &lt;u&gt; &lt;a href="https://www.pccarx.com/PCCANews/PCCAopensregistrationtoallcompoundersforpharmacycompoundingtrainingcoursesonqualitycomplianceandregulatoryrequirements" target="_blank"&gt; eLearning Compounding Training &lt;/a&gt; &lt;/u&gt; .&lt;em&gt; &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;PCCA offers additional resources to our &lt;u&gt;&lt;a href="https://www.pccarx.com/Membership" target="_blank"&gt;members&lt;/a&gt;&lt;/u&gt;, including all courses offered in our &lt;u&gt; &lt;a href="https://pccarx.com/PCCAEducation/eLearning" target="_blank"&gt; eLearning Compounding Training &lt;/a&gt; &lt;/u&gt; , multiple &lt;u&gt; &lt;a href="https://pccarx.com/PCCAEducation/Pharmacy" target="_blank"&gt; online webinars and training sessions &lt;/a&gt; &lt;/u&gt; and, for members with Clinical Services, &lt;u&gt; &lt;a href="https://pccarx.com/PCCAEducation/SpeakersBureau" target="_blank"&gt; Speakers Bureau &lt;/a&gt; &lt;/u&gt; to guide, assist and educate compounding pharmacy staff. Members with Clinical Services may also contact our Clinical Services team for help with formulas and other compounding concerns.&lt;/p&gt;

&lt;p&gt;Look for &lt;strong&gt;USP 797: Revisions &amp; Impacts, &lt;/strong&gt;Part 1 Blog, on March 1.&lt;/p&gt;

&lt;p&gt;&lt;em&gt; The complete version of this article originally appeared in PCCA’s members-only magazine, the Apothagram. &lt;/em&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;div id="addName" style="display: none;"&gt;membership&lt;/div&gt;
</description><guid isPermaLink="false">286</guid></item></channel></rss>